Sana Biotechnology
188 East Blaine Street, Suite 400
Seattle, WA 98102
United States
Website: https://sana.com/
Email: contact@sana.com
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a team of 200 plus scientists, engineers, clinicians and biotechnology veterans creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
27 articles with Sana Biotechnology
-
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
6/14/2021
Sana Biotechnology, Inc. today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.
-
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
6/2/2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021.
-
The additional 100 people will be placed in Seattle, San Francisco, and Cambridge, Mass. by the end of the year.
-
Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
5/5/2021
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the first quarter of 2021.
-
Sana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
5/4/2021
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that it will webcast its presentation at the BofA Securities 2021 Healthcare Conference at 8:00 a.m. PT on Wednesday, May 12, 2021.
-
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
4/27/2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced data from its fusogen technology platform, which are being presented at the virtual American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2021.
-
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
4/9/2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced data from its T cell programs are being presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
-
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
3/24/2021
Expects to present data at multiple scientific conferences in 2021 2020 year-end cash position of $412 million Further strengthened cash position with $627 million in net IPO proceeds
-
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here's a look.
-
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
3/17/2021
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.
-
Money on the Move: February 3-9
2/10/2021
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients. -
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/8/2021
Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering of 27,025,000 shares of its common stock at a public offering price of $25.00 per share, which includes the full exercise by the underwriters of their option to purchase 3,525,000 additional shares of common stock.
-
Sana Announces Upsized Pricing of Initial Public Offering - Feb 04, 2021
2/4/2021
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share.
-
Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.
-
A recap of where life sciences cash has been flowing the past week.
-
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
-
Despite its lofty valuation, the company does not yet have any drugs in the clinic, although it expects to submit Investigational New Drug applications in 2022 and 2023.
-
Biopharma companies raking in the cash with investment rounds and IPO announcements.
-
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
-
Sana Biotechnology Announces Appointments to its Board of Directors
1/8/2021
Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors.